anti-schistosomal

Nilutamide (RU23908), an antineoplastic hormonal agent, is mainly used in the treatment of prostate Y. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors, but not for estrogen, progestogen, or glucocorticoid receptors. Therefore, Nilutamide can block the action of androgens of testicular and adrenal origin that stimulate the growth of malignant and normal prostatic tissue. Prostate Y is mainly androgen-dependent and can be treat with chemical castration or surgical. So far, antiandrogen monotherapy has not consistently been certified to be equivalent to castration.

PHYTOL (trans-Phytol) , a diterpene alcohol from chlorophyll widely used as a food additive and in medicinal fields, shows antinociceptive and antioxidant activities as well as anti-inflammatory and antiallergic effects. It is a specific activator of PPARα.

Hycanthone (Etrenol(mesylate)) is a potent drug of antischistosomal. Hycanthone is a DNA intercalator that inhibits RNA synthesis and DNA topoisomerases I and II. Hycanthone inhibits nucleic acid biosynthesis and inhibits APE1 via direct protein binding(KD: 10 nM).

Insecticidal agent 23 (compound 17) possesses anti-schistosomal properties with low toxicity. It exhibits strong in vitro activity against adult Schistosoma japonicum, with an LC50 (72 h) value of 25.31 μM.

SIRT2-IN-18 (Compound 8) is a potent SIRT2 inhibitor, with IC50 values of 5.3 μM for SmSIRT2 and 12.3 μM for hSIRT2. It demonstrates strong anti-schistosomal activity against Schistosoma mansoni strains from Liberia and Puerto Rico, effectively reducing larval and adult worm pair survival, pairing, and egg production, while exhibiting low cytotoxicity to mammalian cells. Additionally, SIRT2-IN-18 enhances histone H3 hyperacetylation and induces apoptosis through cytochrome c mediation.

Antiparasitic agent-10 (Compound 94) is a potent anti-parasitic agent with significant anti-schistosomal activity, particularly against adult Schistosoma mansoni, making it a promising candidate for Schistosomiasis research as a treatment option [1].